BioAtla Inc (BCAB) USD0.0001

Sell:$0.31Buy:$0.36$0.02 (4.66%)

Prices delayed by at least 15 minutes
Sell:$0.31
Buy:$0.36
Change:$0.02 (4.66%)
Prices delayed by at least 15 minutes
Sell:$0.31
Buy:$0.36
Change:$0.02 (4.66%)
Prices delayed by at least 15 minutes

Company Information

About this company

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Key people

Jay M. Short
Chairman of the Board, Chief Executive Officer, Co-Founder
Richard A. Waldron
Chief Financial Officer, Senior Vice President
Christian Vasquez
Chief Accounting Officer, Controller, Corporate Secretary
Eric L. Sievers
Chief Medical Officer
Lawrence Steinman
Lead Independent Director
Scott A. Smith
Director
Mary Ann Gray
Independent Director
Sylvia Mcbrinn
Independent Director
Susan Moran
Independent Director
Click to see more

Key facts

  • EPIC
    BCAB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US09077B1044
  • Market cap
    $18.91m
  • Employees
    61
  • Shares in issue
    58.40m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.